HOPE Therapeutics, Inc., a wholly owned subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), has signed a binding Letter of Intent to acquire a majority interest in Neurospa TMS Holdings, LLC, a physician-led network of six interventional psychiatry clinics operating on Florida’s Gulf Coast.
The acquisition is expected to be accretive to HOPE’s 2025 revenue and will significantly enhance the company’s growing clinical footprint in Florida. Neurospa is currently revenue-generating and EBITDA positive, offering evidence-based treatments including ketamine infusion therapy, Spravato®, and Transcranial Magnetic Stimulation (TMS) to patients with depression, suicidality, PTSD, and related mental health conditions.
This transaction supports HOPE’s strategy to build a national network of psychiatrist-led clinics that integrate neuromodulation with NMDA-targeted drug therapies being developed by its parent company, NRx Pharmaceuticals.
The acquisition remains subject to financial audits, definitive agreements, and customary closing conditions.
Upcoming Milestones for NRx Pharmaceuticals and HOPE Therapeutics
Q2 2025
Planned ANDA filing for preservative-free ketamine (NRX-100) in currently approved indicationsFiling of a citizen petition to the FDA to remove benzethonium chloride from ketamine productsMid to Late 2025:
NDA submission for NRX-100 (IV ketamine) for Suicidal DepressionNDA submission for NRX-101 (oral D-cycloserine/lurasidone) for bipolar depression with suicidality or akathisiaAnticipated PDUFA decisions before year-end 2025
Ongoing 2025:
Expansion of the HOPE clinic network, targeting 15–20 psychiatry centers in Florida
Completion of additional clinic acquisitions currently under negotiation
Late 2025–2026:
Clinical development of HTX-100, a patentable, pH-neutral subcutaneous ketamine formulation designed for broader accessibility and use
NRx continues to reduce operating costs and forecast forward-looking profitability on a run-rate basis by the end of 2025, driven by streamlined operations, expanded clinical services through HOPE, and strategic product development milestones.
The post HOPE Therapeutics to Acquire Majority Stake in Neurospa TMS, Strengthening Interventional Psychiatry Offerings appeared first on PRISM MarketView.
